Uncategorized

OliX Pharmaceuticals Announces Positive Safety Data and Preliminary Efficacy Effects in a Phase 1 Trial of OLX10212 for Age-Related Macular Degeneration

by Business Wire • 2023/11/29 • 0 Comments

SUWON, South Korea--(BUSINESS WIRE)-- #AMD--OliX announced positive results from a Phase 1 study of OLX10212 for the treatment of Age-Related Macular Degeneration (AMD).

← Harrow Completes Transfer of the TRIESENCE® New Drug Application

Rootstock Manufacturing ERP Selected to Improve Visibility for Optical Frame Manufacturer’s Operations →

Post navigation